Clinical trials: Dementia Alzheimers
Alzheimer's Disease, Mild Cognitive Impairment
Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease
The objectives of this project are to examine amyloid burden and cognition in a group of subjects diagnosed with Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) before and after a six month course of insulin delivered…
- Trial name
- NCT01636596
- Testing
- Insulin LISPRO
- Where
- United States
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Primary Progressive Aphasia, Frontotemporal Dementia
Long-term Effect of TMS in Primary Progressive Aphasia
There are very few treatments for neurodegenerative disorders, and the efficacy of these treatments is generally modest. Recent studies have shown a short-term positive effect of non-invasive neuromodulation techniques such as…
- Conditions
- Primary Progressive Aphasia, Frontotemporal Dementia, Alzheimer Disease
- Trial name
- RECONNECT (NCT05842473)
- Testing
- Transcranial Magnetic Stimulation (active), Language therapy
- Where
- Spain
- Volunteers
- 63 people
- Sponsor
- Hospital San Carlos, Madrid
Alzheimer Disease
AZ@GAME-Eco: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders
The main objective of AZ@GAME ECO is to evaluate the cost-utility of the management of patients suffering from Alzheimer's disease using a serious game providing cognitive and physical straining compared to a usual management.
- Trial name
- AZ@GAME-Eco (NCT03208491)
- Testing
- serious games use, usual care
- Where
- France
- Volunteers
- 136 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Dementia, Alzheimer Disease
The Brain Health Study: A Pragmatic, Patient-Centered Trial
The eRADAR Brain Health Study is an embedded, pragmatic clinical trial to determine whether targeted screening for dementia using the eRADAR algorithm increases dementia detection within primary care compared to usual care.
- Trial name
- eRADAR (NCT05905796)
- Testing
- Brain Health Assessment
- Where
- 3 sites in United States
- Volunteers
- 1,261 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Cognitive Decline, Cognitive Dysfunction
Brain Vascular and Neurocognitive Health
The overall research objective of this proposal is to determine the acute and chronic impact of transcranial photobiomodulation on indices of cerebral vascular health and neurocognitive function.
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Alzheimer Disease, Vascular Disease, Peripheral
- Trial name
- NCT06497413
- Testing
- Transcranial Photobiomodulation, Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Arlington
Alzheimer's Disease
Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants
This is a longitudinal, follow-up study in participants with Alzheimer's disease (AD) who previously participated in study BP29409 (NCT02187627).
- Trial name
- NCT02792179
- Testing
- [18F]RO6958948
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease, Hearing Loss
Auditory Rehabilitation and Cognition in Alzheimer Patients
Alzheimer disease is a neurodegenerative disease. Recent studies suggest that subjects with hearing loss are more likely to develop Alzheimer's disease.
- Trial name
- RACO-MA (NCT03002142)
- Testing
- Hearing aids
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Tours
Alzheimer Disease
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
The primary objectives of this study are to characterize [18F]molecular neuroimaging (MNI)-1020, a positron emission tomography (PET) radioligand for imaging tau pathology, to visually and quantitatively assess and compare brain…
- Trial name
- NCT03239561
- Testing
- [18F]MNI-1020
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were…
- Trial name
- NCT05476783
- Testing
- TB006
- Where
- 13 sites in United States
- Volunteers
- 119 people
- Sponsor
- TrueBinding, Inc.
Alzheimer's Disease
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
The Connection Study is a six-month confirmatory Phase 3 study to determine the safety and efficacy of Dimebon in the treatment of mild-to-moderate Alzheimer's disease (AD).
- Trial name
- CONNECTION (NCT00675623)
- Testing
- Dimebon
- Where
- 28 sites in United States
- Volunteers
- 598 people
- Sponsor
- Medivation, Inc.
Mild Cognitive Impairment
CBD for Individuals at Risk for Alzheimer's Disease
This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with…
- Trial name
- NCT05822362
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- University of Colorado, Denver
Autosomal Dominant Cases of Alzheimer 's Disease
Genetics of Mendelian Forms of Young Onset Alzheimer Disease
Genetics of mendelian forms of young onset Alzheimer Disease (GMAJ project) Introduction : Autosomal dominant forms of Alzheimer disease (AD) are characterized by young age of onset.
- Trial name
- GMAJ (NCT01622894)
- Testing
- Genetic-Tailored AntiThrombotic Strategy
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Alzheimer Disease
Late Onset Alzheimer's Disease
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African…
- Trial name
- LOAD (NCT05010603)
- Testing
- Blood Draw, Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test
- Where
- 12 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Alzheimer's Disease
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1) safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid load as measured by positron emission…
- Trial name
- SUMMIT AD (NCT01254773)
- Testing
- Experimental Bapineuzumab
- Where
- 28 sites in United States
- Volunteers
- 146 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer Disease
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease
Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Alzheimer's disease (AD).
- Trial name
- NCT04228666
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences LLC
Alzheimer's Disease
A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil
This study is intended to determine the safety and tolerability of ASP0777 in subjects with Alzheimer's Disease (AD) taking a stable dose of donepezil.
- Trial name
- NCT01406145
- Testing
- ASP0777
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Alzheimer's Disease
Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease
Alzheimer's disease is a neurodegenerative disease. Numerous studies have reported that β-amyloid (Aβ) is an important marker for the diagnosis of AD.
- Trial name
- NCT04926272
- Testing
- 18F-92
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Alzheimer's Disease
Imaging Inflammation in Alzheimer's Disease
This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein…
- Trial name
- NCT02831283
- Testing
- 11C-PBR28, 18F-Florbetaben, Lumbar puncture (optional)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Patrick Lao
Alzheimer's Disease
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
This is a single centre, 2 part study in older subjects. Part 1 (Pharmacokinetic [PK] Assessment) is a double blind, randomized, placebo-controlled 4-period crossover study investigating the PK profile of four different doses of…
- Trial name
- NCT01702480
- Testing
- GSK2981710
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.